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Results for SR-GVHD in children following treatment with
Prochymal or Placebo
CR OR (CR1 PR) Progression Survival
Prochymal/
Placebo
Prochymal/
Placebo
Prochymal/
Placebo
Prochymal/
Placebo
Day 28 36% / 21% 64% / 36% 14% / 50% 93% / 86%
Day 42 57% / 21% 64% / 50% 29% / 43% 79% / 79%
Day 100 64% / 29% 71% / 50% 21% / 43% 79% / 50%
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SINGLE PRE-TRANSPLANT TREATMENT WITH GM-CSF-SECRETING
MYELOID LEUKEMIA CELL VACCINE COMBINED WITH AUTOLOGOUS-
BMT SIGNIFICANTLY IMPROVES SURVIVAL OF MYELOID LEUKEMIA
CHALLENGED MICE
Zilberberg, J., Friedman, T.M., Korngold, R. Hackensack University
Medical Center, Hackensack, NJ
A number of pre-clinical and recent clinical trials have demon-
strated the efficacy of tumor vaccines engineered to secrete GM-
CSF (GVAX) for the treatment of solid tumors and hematological
malignancies. We investigated the graft-versus-leukemia (GVL)
effects of a GM-CSF-secreting myeloid leukemia cell vaccine in
a murine bone marrow transplantation (BMT) model using the
MMB3.19 leukemia cell line, of C57BL/6 (B6) origin. Our approach
consisted of a recipient GVAX-preconditioning strategy, prior to
transplantation, that differed from current treatment designs in
that post-BMTdonor immune reconstitution was not required in or-
der to observe a significant GVL response, and a single GVAX injec-
tion, as opposed tomultiple treatments, was sufficient to significantly
improve survival of leukemia-challenged mice. B6 Mice received
a single subcutaneous preconditioning infusion of 2105 irradiated
GVAX tumor cells. Seven days later, mice were lethally irradiated
with 850 cGy and transplanted with 2106 anti-T cell-depleted B6
BM cells, alone or in combination with 4106 donor lymphocytes
(DL). On day 1 post-BMT, mice were challenged with 1105
MMB3.19 cells (i.p). Statistical comparisons using a non-parametric
log-rank test showed enhanced survival rate in the GVAX-precondi-
tioned group 70 days post-BMT (60% survival), compared to: DL
alone (10% survival, MST5 26 d, P5 0.01); GVAX given 1 day
post-BMT (20% survival, MST5 26.5 d, P5 0.01); and precondi-
tioning with irradiated tumor cells (30%, MST5 37.5 d,
P5 0.01). GVAX-preconditioned mice receiving no DL also had
significantly increased survival than DL alone (40% survival,
MST5 37.5 d, P5 0.02). These results indicate that a single pre-
transplant GVAX dose can significantly improve survival of
MMB3.19 challenged mice and suggests that after host irradiation,
immune cells exposed to GVAX remain capable of mediating signif-
icant GVL responses, even in the absence of DL.381
TREATMENT OF STEROID-REFRACTORY ACUTE GVHDWITH MESENCHY-
MAL STEM CELLS IMPROVES OUTCOMES IN PEDIATRIC PATIENTS;
RESULTS OF THE PEDIATRIC SUBSET IN A PHASE III RANDOMIZED,
PLACEBO-CONTROLLED STUDY
Szabolcs, P.1, Visani, G.2, Locatelli, F.3, Kleiner, G.4, Talano, J.5,
Nemecek, E.6, Kurtzberg, J.1 1Duke University Medical Center, Dur-
ham, NC; 2Universita` degli Studi di Pesaro, Italy; 3 IRCCS Policlinico
San Matteo, Pavia, Italy; 4University of Miami, Miami, FL; 5Medical
College of Wisonsin, Milwaukee, WI; 6OHSU Cancer Institute, Portland,
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Successful treatment of steroid-refractory aGVHD (SR-GVHD)
following allogeneic hematopoietic cell transplantation remains
a significant challenge. Because of their immunomodulatory proper-
ties and safety profile, adult mesenchymal stem cells (MSCs) have
been proposed as a treatment for SR-GVHD. Intravenous allogeneic
MSC therapy (Prochymal) for SR-GVHDwas independently eval-
uated in the pediatric subset of a double-blind, placebo-controlled
study (Protocol 280).
Methods: Pediatric patients (\ 18 yrs) with grade B-D SR-GVHD
were randomized to receiveProchymal or placebo in addition to stan-
dard of care, including institutionally selected second line agent. Pa-
tients received 8 infusions of 2 106 cells/kg for 4 weeks (or volume
equivalent for placebo), with 4 more infusions weekly in the case of
a partial response (PR). The primary endpoint was durable complete
response (CR$ 28 days); secondary endpoints included incidence of
CR, PR and progression through 100 days, survival, and safety.
Results: Twenty-eight children were randomized to Prochymal
(50% male, 79% Caucasian) or placebo (71% male, 71% Cauca-
sian), with a median age of 7 yrs (range 1-15) and 10 years (range
1-18), respectively. The dominant transplant graft was cord blood(71% Prochymal, 57% placebo), with mostly unrelated donors
(93% vs 79%, respectively). The median duration of aGVHD prior
to enrollment was 20 days for Prochymal and 8 days for placebo
(p\0.05). At baseline, aGVHD grades B:C:D were 3:8:3 for
both arms. For Prochymal, organ involvement was 64% skin,
43% GI, and 36% liver. For placebo patients, organ involvement
was 57% skin, 79% GI, and 29% liver. Durable CR was 64% for
Prochymal and 43% for placebo. Prochymal improved rates of
CR and OR (Table). The median time to CR was 25 days vs 63
days. The 25% percentile of the survival function after study start
was 139 days for Prochymal and 50 days for placebo. The safety
data showed no infusional toxicity and no evidence of Prochymal
leading to ectopic tissue. There were no AEs leading to discontin-
uation of therapy.
Conclusion: In a SR-GVHD population in which 79% of patients
had grade C/D disease, the addition of Prochymal to standard of
care doubled 28 day CR rates and reduced progression by half. Re-
sponse at 28 days correlated with improved 100 day survival. Given
increased response rates and a well-tolerated safety profile, MSCs
appear to be a safe and effective therapy in the treatment of pediatric
patients with SR-GVHD.382
EFFECT OF CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4 (CTLA-4) HAPLO-
TYPE ON ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
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CTLA-4 is a negative regulator for activated T cells and the asso-
ciation of CTLA-4 polymorphisms with autoimmune diseases has
been reported. The present study evaluated the effect of donor
CTLA-4 haplotype on the immune reaction after allogeneic hemato-
poietic stem cell transplantation (HSCT) such as graft-versus-host
disease (GVHD) and graft-versus-leukemia (GVL) effect. We ana-
lyzed 147 cases of Japanese HLA-matched sibling recipients and
their donors who had undergone allogeneicHSCT for the treatment
of hematological malignancies between 1987 and 2006 at the Na-
goya University Hospital and the Japanese Red Cross Nagoya First
Hospital. All recipients received T-cell-replete transplantation.
Cyclosporine and short-term methotrexate were used as GVHD
prophylaxis. Genotyping of three single nucleotide polymorphisms
(SNPs) in CTLA-4 (-318, +49, CT60) were performed by Taq-
man-PCR method and/or DNA sequencing method using genomic
DNA obtained from donor peripheral blood mononuclear cells
(PBMCs). Their haplotypes were determined based on the HapMap
database. Multivariate analyses were performed using Cox propor-
tional-hazard model. Age, conditioning, disease risk and graft source
were included as covariates. According to the HapMap database,
CTLA-4 haplotype (-318, +49, CT60) could be classified into three
types (C-G-G, C-A-A, T-A-G) in Japanese population. In this study,
the proportion of the haplotype C-G-G, C-A-A, and T-A-G were
59.5%, 30.6%, and 9.9%, respectively. Recipients who received
stem cells from a donor with the C-A-A haplotype showed signifi-
cantly lower disease relapse (HR: 0.53, 95%CI: 0.29-0.96,
Poster Session II S299p5 0.035) and higher overall survival (HR: 0.60, 95%CI: 0.36-0.99,
p5 0.047) than those who received stem cells from a donor without
the C-A-A haplotype. Additionally, the group with the
C-A-A haplotype exhibited high disease-free survival (HR: 0.66,
95%CI: 0.41-1.06, p5 0.085), compared with the group without
the haplotype C-A-A. The presence or absence of the C-A-A haplo-
type did not affect the incidence of acute and chronic GVHD, and
non-relapse mortality. This is the first report described the effect
of CTLA-4 haplotype, but not each SNP, on allogeneic HSCT.
Since the presence of CTLA-4 haplotype C-A-A reduced the risk
of relapse and improved survival after allogeneic HSCT, CTLA-4
haplotype may provide useful information for donor selection.Blockade of two independent innate immunity pathways syn-
ergistically prevent lethal graft-versus-host disease
Groups n
Survival at
day 150
Survival at
day 1100
TCD BM alone 10 100% 100%
Wildtype 1 isotype 10 20% 10%
Wildtype 1 anti-C5 10 40% 30%
MyD88-/- 1 isotype 10 50% 20%
MyD88-/- 1 anti-C5 10 90% 80%
P\0.01, MyD88-/-1 anti-C5 vs. other groups. A representative exper-
iment of three is shown.383
EPIGENETICCONTROLOFGVHDANDGVLUSINGTHEHYPOMETHYLATING
AGENT AZACITIDINE
Choi, J., Ritchey, J., DiPersio, J.F. Washington University School of
Medicine, St. Louis, MO
Allogeneic bone marrow transplantation (BMT) represents the
most effective treatment for patients with high risk and relapsed
hematologic malignancies because allogeneic donor T cells pro-
vide a graft-versus-leukemia (GvL) effect. However, the same cells
can cause graft-versus-host disease (GvHD), one of the major
complications. Regulatory T cells (Tregs) have been shown to
suppress GvHD while preserving GvL, their use provides a prom-
ising strategy in the allogeneic transplant setting if three major
obstacles will be overcome: 1) the low numbers of Tregs, 2)
loss of suppressor activity following ex vivo expansion and 3) the
lack of Treg-specific markers to purify ex vivo expanded Tregs.
The FOXP3 transcription factor, which is exclusively expressed
in Tregs, can convert effector T cells (Teff) into Tregs when ec-
topically overexpressed. The Foxp3 locus is unmethylated in Tregs
while highly methylated and silenced in all other T cells. The hy-
pomethylating agent azacitidine (AzaC) can modulate this methyl-
ation status and induce stable FOXP3 expression (.7 days) in
Teff. Furthermore, we have shown that these AzaC-induced
FOXP3 +T cells are suppressive phenotype in vitro. Thus, we hy-
pothesize that AzaC treatment of mice after allogeneic BMT will
dramatically mitigate GvHD while preserving GvL via upregula-
tion of Foxp3 in alloreactive Teff.
In murine T cell depleted (TCD) BMT model (B6/ Balb/c)
with delayed infusion of conventional T cells (Tconv) (2X106) at
day 11 post BMT, followed by subcutaneous treatment of AzaC
(2 mg/kg at days 15, 17, 19, and 21 post BMT), we found that
AzaC dramatically suppressed GvHD caused by allogeneic donor
T cells while maintaining donor engraftment of all lineages. The
AzaC group had significantly higher FOXP3 +Tregs than in PBS
control group and that these Tregs were derived from donor T
cells, suggesting that the suppression of GvHD was mediated by
AzaC-induced Tregs. We further tested whether AzaC treatment
of mice transplanted with allogeneic T cells preserve GvL while
mitigating GvHD. Using the same murine allogeneic BMT
model, Click Beetle Red luciferase-expressing A20 leukemia cells
(Balb/c derived; 1X104) were injected with TCD BM and
10106 Tconv and in vivo bioluminescence imaging was per-
formed to assess tumor burden. We found that AzaC treatment
mitigated GvHD without abrogating GvL or donor engraftment.
Thus, the adminstration of hypomethylating agents like AzaC
might be a promising strategy to treat GvHD.384
BLOCKADE OF TWO INDEPENDENT INNATE IMMUNITY PATHWAYS
SYNERGISTICALLY PREVENT LETHAL GRAFT-VERSUS-HOST DISEASE
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Graft-versus-host disease (GVHD) is a major complication fol-
lowing hematopoietic cell transplantation. Innate immunity plays
a major role in the development of GVHD both by aiding allogeneic
T cell responses and by damaging target organs directly. MyD88 is
an adaptor protein for the majority of toll-like receptors. The com-plement system is a central component of the innate immune
response. We studied the role of these two pathways in the develop-
ment of GVHD using the C57BL/6 into BALB/c model. Lethally
irradiated recipients of MyD88-/- T cells survived slightly longer
than recipients of wild type cells (median survival time: 48 vs. 32
days, P\0.05). Similarly, treatment with an anti-C5 antibody (clone
BB5.1, 1 mg/dose, i.p., three times a week for 4 weeks), that blocks all
three pathways of complement activation and prevents cell lysis, also
moderately prolonged the survival of the mice with GVHD com-
pared with the isotype control group (median survival time: 43 vs.
32 days). Treatment of MyD88-/- T cell recipients with anti-C5 an-
tibody protected 80% of the animals from lethal GVHD at 100 days
post transplantation, while only 20% in the MyD88-/- T cell recipi-
ents treated with isotype antibody group and 30% in the wildtype T
cell recipients treated with anti-C5 antibody group survived (Table,
P\0.01, compared with other groups). All MyD88-/- T cell recipi-
ents treated with anti-C5 antibody developed GVHD.However, the
disease was less severe in these animals than those in the recipients of
a single pathway blockade as measured by body weight and other
clinical signs of GVHD. The anti-C5 antibody did not seem to pre-
vent GVHD through inhibiting T cell activation and expansion
because it did not inhibit mixed lymphocyte reactions. Levels of mul-
tiple pro-inflammatory cytokines were lower in the MyD88-/- T cell
recipients treated with anti-C5 antibody compared with those in the
control groups. These data clearly demonstrate that, even though
blockade of MyD88 or complement pathway alone may prevent
GVHD, GVHD can be better controlled by blocking both
MyD88 and complement pathways.385
MYCOPHENOLATE PHARMACOKINETICS AND ASSOCIATION WITH
RESPONSE TO ACUTE GRAFT VS HOST DISEASE (GVHD) TREATMENT
Jacobson, P.A.1, Juang, J.2, Wu, J.3, Kim, M.1, Logan, B.4, Alousi, A.5,
Grimley, M.6, Bolan˜os-Meade, J.7, Ho, V.8, Levine, J.E.9,
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Pharmaceuticals, Cambridge,MA; 3The EMMESCorporation, Rockville,
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Mycophenolate mofetil (MMF) is a common and effective pro-
phylactic immune suppressant that promotes hematopoietic cell en-
graftment and prevents graft vs host disease (GVHD) after
allogeneic hematopoietic stem cell transplant (HCT). However,
there is limited data as to the effectiveness of MMF plus high dose
corticosteroids for the treatment of acute GVHD and even less
data regarding the pharmacokinetic disposition and exposure-re-
sponse relationship of mycophenolate in individuals with GVHD.
Mycophenolate pharmacokinetics were studied in a multi-center
CTN randomized phase II trial evaluating the effectiveness of
MMFas one if four novel agents added to steroids as initial treatment
of acute GVHD. Thirty-two patients randomized to receiveMMF 1
gm twice daily who underwent pharmacokinetic sampling in weeks 1
and 2 were studied. Median age was 416 13.6 years. Twenty one
(65.6%), 5 (15.6%), 6 (18.8%) patients had a complete response
(CR), partial response (PR) or lesser response by day 28, respectively.
